CanBas Co., Ltd.
4575.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.78B
Close$
Share Statistics
| Market cap | $15.78 Billion |
|---|---|
| Enterprise Value | $14.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-66.43 |
| Beta | -0.83 |
| Outstanding Shares | 19,703,000 |
Return
| Return on Equity | -79.71% |
|---|---|
| Return on Assets | -73.66% |
| Return on Invested Capital | -82.00% |
Valuation & Multiples
| P/E Ratio | -12.06 |
|---|---|
| PEG | -36.11 |
| Price to Sales | - |
| Price to Book Ratio | 9.65 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.65 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CanBas Co., Ltd.
18 employees
CEO: Takumi Kawabe CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at...